JPH09502430A - ガストリンとcckレセプタリガンド - Google Patents
ガストリンとcckレセプタリガンドInfo
- Publication number
- JPH09502430A JPH09502430A JP7506306A JP50630695A JPH09502430A JP H09502430 A JPH09502430 A JP H09502430A JP 7506306 A JP7506306 A JP 7506306A JP 50630695 A JP50630695 A JP 50630695A JP H09502430 A JPH09502430 A JP H09502430A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- prepared
- methyl
- nmr
- except
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/65—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/82—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/48—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring being part of a condensed ring system of the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D333/70—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/56—Ring systems containing bridged rings
- C07C2603/58—Ring systems containing bridged rings containing three rings
- C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
- C07C2603/74—Adamantanes
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Compounds Of Alkaline-Earth Elements, Aluminum Or Rare-Earth Metals (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.下記式(Ia),(Ib)または(Ic)の化合物 (式中、Aは二つの環に共通な原子が単結合もしくは多重結合で結合している 二つの縮合環[WとXは隣接する原子上の水素を置換する基]、またはAは次の 式(Id)で表される基であり、 mは0ないし6の整数[ただしR1がハロゲン基でないときは2より大きくは ない]、 R1はハロゲン、アミノ、アミジノ、ニトロ、シアノ、ヒドロキシ、スルファ モイル、ヒドロキシスルホニル、カルボキシ、エステル化カルボキシ、アミド化 カルボキシ、テトラゾリル、炭素数1〜3のアルキル、アリール、置換アリール 、炭素数1〜6のヒドロキシアルキル、炭素数1〜6のハロアルキル、炭素数1 〜6のアルキルカルボキシアミノ、HON=C−、R27-SO2−NH−、R27− SO2−NH−CO−、R27−CO−、R27−CO−NH−、R27-CO−NH− SO2−、R27−CO−NH−SO−、R27−NH−SO2−[ここでR27はH〔 R27がイオウ−原子と結合している場合を除く〕、炭素数1〜6のアルキ ル、炭素数1〜6のハロアルキル、アリールもしくは置換アリール、またR28は H、炭素数1〜6のアルキル、炭素数1〜6のハロアルキル、アリールもしくは 置換アリール、−OHもしくは−CN〔mが2以上のとき、R1基は上述の各基 から独立に選択される〕]、 Kは−O−、−S−、−CH2−、−N(R2)−もしくは−N(COR2)−(こ こでR2はHもしくは炭素数1〜3のアルキルである)、 Wはカルボニル、スルホニルもしくはスルフィニル基[ただしWとXの少なく とも一方はカルボニルである]、 YはR3-N(R4)−もしくはR3'−O−(ここでR3はHもしくは炭素数1〜1 5のヒドロカルビル、ハロゲン原子で置換されることのあるヒドロカルビル部分 における一個以上の水素原子、窒素、酸素もしくはイオウ原子で置換されること のあるヒドロカルビル部分における二個までの炭素原子、R3'は炭素数6〜15 のヒドロカルビル、ハロゲン原子で置換されることのあるヒドロカルビル部分に おける一個以上の水素原子、窒素、酸素もしくはイオウ原子で置換されることの あるヒドロカルビル部分における二個までの炭素原子、R4はH、炭素数1〜3 のアルキル、カルボキシメチルもしくはエステル化カルボキシメチル[ただしY は−O−O−基とはならない]、 Zは、 i)−O−R5[R5はH、炭素数1〜5のアルキル、フェニル、置換フェニル、 ベンジルもしくは置換ベンジル]; ii) [ここでQはH、炭素数1〜5のヒドロカルビルもしくは−R6−U−〔R6は単 なる結合線もしくは炭素数1〜5のアルキレン、そしてUはアリール、置換アリ ール、ヘテロ環、置換ヘテロ環もしくはシクロアルキルである〕]; iii) [式中、aは0もしくは1、bは0〜3の整数、 R7はHもしくはメチル、 R8はHもしくはメチル、またはR8がCH2=でQ’が存在しないか、または R7とR8が三員環から七員環までを形成するよう結合し、 R9は単なる結合線 、−CHOH−もしくは−C(O)−、 Q’は上述のQと同じかもしくは−R6−(C(O))d−L−(C(O))e−R5 〔ここでR5とR6は上述の通り、LはO、Sもしくは−N(R10)−{ここでR10 は上述のR4と同じ}、dとeは0もしくは1{ただしd+e<2}〕;または Q’とR8はともに三員環から七員環までを形成するよう結合している炭素原子 であり、 Qは上述の通りであるか;またはQとR8はともに式−(CH2)f−V−(CH2)g −の基を形成するか;〔ここでVは−S−、−S(O)−、−S(O)2−、−C H2−、−CHOH−もしくは−C(O)−、fは0〜2の整数、gは0〜3の 整数〕;またはQ’が−R6−Uで、Uが芳香族のとき、QはさらにUと結合す るメチレン鎖のこともある〔このメチレン鎖はR6とUの結合に対してオルト位 をなす〕、 TはH、シアノ、炭素数1〜4のアルキル、−CH2OH、カルボキシ、エス テル化カルボキシ、アミド化カルボキシもしくはテトラゾリル];または iv) [式中、R5とR6は上述の通り、R11は上述のR4と同じ、R12とR13は独立 に単なる結合線もしくは炭素数1〜3のアルキレン〔ただしR12とR13は一緒に なって式中の環に2〜4個の炭素原子を与える〕]である)またはこれら化合物 の薬理学的に許容可能な塩。 2.下記式 (式中、WとXは、隣接する炭素原子に結合し、R32はH、炭素数1〜3のア ルキルもしくは炭素数1〜3のアルキルカルボキシ、またL’は−NR32−、− O−もしくは−S−である) (式中、W、X、Y、Z、R1およびmは請求の範囲第1項で定義した通りで ある) 3.前記R3は炭素数6〜8の直鎖もしくは分枝鎖アルキルまたはR23−(CH2)p −(ここでR23はフェニル、1−ナフチル、2−ナフチル、インドリル、ノル ボルニル、アダマンチル、シクロヘキシルもしくはシクロヘプチルの各基であり 、pは0〜3の整数)である請求の範囲第1項または第2項記載の化合物。 4.前記Wはカルボニル、前記Xはスルホニルである請求の範囲第1項ないし第 3項のいずれか一項記載の化合物。 5.前記Wがカルボニル、前記Xもカルボニルである請求の範囲第1項ないし第 3項のいずれか一項記載の化合物。 6.前記Wはスルホニル、前記Xはカルボニルである請求の範囲第1項ないし第 3項のいずれか一項記載の化合物。 7.前記mは0である請求の範囲第1項ないし第6項のいずれか一項記載の化合 物。 8.前記−X−Yは−CONR3R4(R3とR4は請求の範囲第1項で定義した通 り)であり、−W−Zは (式中、R29、R30およびR31は独立にHまたは炭素数1〜3のアルキル;U ’は(置換されることのある)芳香族奇異;nは1または2;Yは−CO2H、 テトラゾリル、エステル化カルボキシ、アミド化カルボキシ、R27−SO2−N H−、R27−SO2−NH−、R27−SO2−NH−CO−、R27−CO−NH− SO2−、R27−CO−NH−SO−、R27−NH−SO2−(R27とR28は請求 の範囲第1項で定義した通り)である請求の範囲第1項記載の化合物。 9.5−(1S−(3,5−ジカルボキシフェニルアミノカルボニル)−2−フ ェニルエチルアミノカルボニル)−6−(1−アダマンタンメチルアミノカルボ ニル)−インドール、5−(1R−(3,5−ジカルボキシフェニルアミノ−カ ルボニル)−2−フェニルエチルアミノカルボニル)−6−(1−アダマンタン メチルアミノカルボニル)−インドール、5−(1R−(3,5−ジカルボキシ フェニルアミノカルボニル)−2−(2−フルオロフェニル)エチルアミノカル ボニル)−6−(1−アダマンタンメチルアミノカルボニル)−インドール、5 −(1S−(3,5−ジカルボキシフェニルアミノカルボニル)−2−(2−フ ルオロフェニル)エチルアミノカルボニル)−6−(1−アダマンタンメチルア ミノカルボニル)−インドール、5−(1R−(3,5−ジカルボキシフェニル アミノカルボニル)−2−(4−ヒドロキシフェニル)エチルアミノカルボニル )−6−(1−アダマンタンメチル−アミノカルボニル)−インドール、5−( 1S−(3,5−ジカルボキシフェニルアミノカルボニル)−2−(4−ヒドロ キシフェニル)エチルアミノカルボニル)−6−(1−アダマンタンメチル−ア ミノカルボニル)−インドール、5−(1S−(3,5−ジカルボキシフェニル アミノカルボニル)−2−(フェニルエチルアミノカルボニル)−6−(1−ア ダマンタンメチル−アミノカルボニル)−ベンジミダゾール、5−(1R−(3 ,5−ジカルボキシフェニルアミノカルボニル)−2−(フェニルエチルアミノ カルボニル)−6−(1−アダマンタンメチル−アミノカルボニル)−ベンジミ ダゾール、5−(1R−(3,5−ジカルボキシフェニルアミノカルボニル)− 2−(2−フルオロフェニル)エチルアミノカルボニル)−6−(1−アダマン タンメチル−アミノカルボニル)−ベンジミダゾール、5−(1S−(3,5− ジカルボキシフェニルアミノカルボニル)−2−(2−フルオロフェニル)エチ ルアミノカルボニル)−6−(1−アダマンタンメチルアミノカルボニル)−ベ ンジミダゾール、5−(1S−(3,5−ジカルボキシフェニルアミノカルボニ ル)−2−(3−フルオロフェニル)エチルアミノカルボニル)−6−(1−ア ダマンタンメチルアミノカルボニル)−ベンジミダゾール、5−(1R−(3, 5−ジカルボキシフェニルアミノカルボニル)−2−(3−フルオロフェニル) エチルアミノカルボニル)−6−(1−アダマンタンメチルアミノカルボニル) −ベンジミダゾール、5−(1R−(3,5−ジカルボキシフェニルアミノカル ボニル)−2−(4−ヒドロキシフェニル)エチルアミノカルボニル)−6−( 1−アダマンタンメチルアミノカルボニル)−ベンジミダゾール、5−(1S− (3,5−ジカルボキシフェニルアミノカルボニル)−2−(4−ヒドロキシフ ェニル)エチルアミノカルボニル)−6−(1−アダマンタンメチルアミノカル ボニル)−ベンジミダゾール、5−(1S−(3,5−ジカルボキシフェニルア ミノカルボニル)−2−(2−フルオロフェニル)エチルアミノカルボニル)− 6−(1−シクロヘプタンメチルアミノカルボニル)−ベンジミダゾール、5− (1S−(3−ベンゾイルアミノフルホニルフェニルアミノカルボニル)−2− フェニルエチルアミノカルボニル)−6−(1−アダマンタンメチルアミノカル ボニル)−ベンジミダゾール、および5−(1S−(3−ベンゾイルアミノフル ホニルフェニルアミノカルボニル)−2−(2−フルオロフェニル)エチルアミ ノカルボニル)−6−(1−アダマンタンメチルアミノカルボニル)−ベンジミ ダゾールから選択される化合物。 10.請求の範囲第1項ないし第9項のいずれか一項記載の化合物と薬理学的に 許容可能な希釈剤または担体を含む薬剤。 11.前記Wがカルボニルである請求の範囲第1項記載の化合物を調製する方法 であって、式YH(Yは請求の範囲第1項で定義した通り)の化合物を、下記式 (II)の化合物と反応させる方法 (式中、Bは、 または、 [式中、A、R1、m、KおよびXは請求の範囲第1項で定義した通り]である )。 12.前記Wがスルホニルである請求の範囲第1項記載の化合物を調製する方法 であって、式R3−Hal(Halはハロゲン原子を表し、R3は請求の範囲第1 項で定義した通り)の化合物を、下記式(VIII)の化合物と反応させ (式中、Bは請求の範囲第1項で定義した通り)、さらにアルコキシドと反応 させる工程を含む方法。 13.前記WまたはXがスルホニルである請求の範囲第1項記載の化合物を調製 する方法であって、式R3−Hal(Halはハロゲン原子を表し、R3は請求の 範囲第1項で定義した通り)の化合物を、下記式(XI)の化合物と反応させ (式中、Bは請求の範囲第1項で定義した通り)、さらにアルコキシドと反応 させる工程を含む方法。 14.請求の範囲第1項ないし第9項のいずれか一項記載の化合物を薬理学的に 許容可能な希釈剤または担体と混合する工程を含む請求の範囲第10項記載の薬 剤を調製する方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB939316608A GB9316608D0 (en) | 1993-08-10 | 1993-08-10 | Gastrin and cck receptor ligands |
GB9316608.0 | 1993-08-10 | ||
GB9410688.7 | 1994-05-27 | ||
GB9410688A GB9410688D0 (en) | 1993-08-10 | 1994-05-27 | Gastrin and CCK receptor ligands |
PCT/GB1994/001741 WO1995004720A2 (en) | 1993-08-10 | 1994-08-09 | Gastrin and cck receptor ligands |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH09502430A true JPH09502430A (ja) | 1997-03-11 |
JP3980052B2 JP3980052B2 (ja) | 2007-09-19 |
Family
ID=26303354
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50630695A Expired - Lifetime JP3980052B2 (ja) | 1993-08-10 | 1994-08-09 | ガストリンとcckレセプタリガンド |
Country Status (18)
Country | Link |
---|---|
US (1) | US5919829A (ja) |
EP (1) | EP0720601B1 (ja) |
JP (1) | JP3980052B2 (ja) |
AT (1) | ATE197146T1 (ja) |
AU (1) | AU682051B2 (ja) |
CA (1) | CA2167154A1 (ja) |
DE (1) | DE69426205T2 (ja) |
DK (1) | DK0720601T3 (ja) |
ES (1) | ES2152989T3 (ja) |
FI (1) | FI115050B (ja) |
GR (1) | GR3035100T3 (ja) |
HU (1) | HU222178B1 (ja) |
NO (1) | NO306945B1 (ja) |
NZ (1) | NZ269827A (ja) |
PL (1) | PL181782B1 (ja) |
PT (1) | PT720601E (ja) |
SG (1) | SG52229A1 (ja) |
WO (1) | WO1995004720A2 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006501194A (ja) * | 2002-07-03 | 2006-01-12 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Cck−1受容体モジュレーター |
WO2006095922A1 (ja) * | 2005-03-10 | 2006-09-14 | Kyoto Pharmaceutical Industries, Ltd. | テトラヒドロイソキノリン化合物およびその医薬用途 |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995032949A1 (en) * | 1994-05-27 | 1995-12-07 | James Black Foundation Limited | Gastrin and cck antagonists |
AU3459497A (en) * | 1996-07-12 | 1998-02-09 | Chugai Seiyaku Kabushiki Kaisha | Cancer cell proliferation inhibitors |
US6747027B1 (en) | 1996-07-22 | 2004-06-08 | Pharmacia Corporation | Thiol sulfonamide metalloprotease inhibitors |
RU2221781C2 (ru) * | 1996-07-22 | 2004-01-20 | Монсанто Компани | Тиолсульфоновые соединения в качестве ингибитора матриксной металлопротеазы и способы лечения |
SE9704544D0 (sv) | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
SE9704545D0 (sv) | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
AU9297998A (en) * | 1998-05-15 | 1999-12-06 | Guilford Pharmaceuticals Inc. | Carboxamide compounds, compositions, and methods for inhibiting parp activity |
EP1178969B1 (en) * | 1998-11-09 | 2005-07-13 | James Black Foundation Limited | Gastrin and cholecystokinin receptor ligands |
US6800646B1 (en) | 1999-02-08 | 2004-10-05 | Pharmacia Corporation | Sulfamato hydroxamic acid metalloprotease inhibitor |
HUP0202214A3 (en) | 1999-04-09 | 2002-12-28 | Astrazeneca Ab | Adamantane derivatives, preparation and use thereof |
EP1184373A4 (en) | 1999-04-20 | 2004-10-20 | Meiji Seika Kaisha | TRICYCLIC CONNECTIONS |
US7045287B2 (en) * | 1999-07-20 | 2006-05-16 | Agilent Technologies, Inc. | Method for contacting fluid components with moieties on a surface |
SE9904505D0 (sv) | 1999-12-09 | 1999-12-09 | Astra Pharma Prod | Novel compounds |
TWI258462B (en) | 1999-12-17 | 2006-07-21 | Astrazeneca Ab | Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same |
GB0013737D0 (en) | 2000-06-07 | 2000-07-26 | Astrazeneca Ab | Novel compounds |
SE0103836D0 (sv) | 2001-11-16 | 2001-11-16 | Astrazeneca Ab | Novel compounds |
SE0200920D0 (sv) * | 2002-03-25 | 2002-03-25 | Astrazeneca Ab | Novel compounds |
MXPA04010555A (es) | 2002-04-25 | 2005-02-17 | Pharmacia Corp | Acidos piperidinil- y piperazinil-sulfonilmetil hidroxamicos y su uso como inhibidores de proteasa. |
SE0300480D0 (sv) | 2003-02-21 | 2003-02-21 | Astrazeneca Ab | Novel compounds |
GB0312609D0 (en) | 2003-06-02 | 2003-07-09 | Astrazeneca Ab | Novel compounds |
PT1651621E (pt) * | 2003-08-08 | 2008-09-30 | Janssen Pharmaceutica Nv | Compostos de 2-(quinoxalin-5-ilsulfonilamino)-benzamida como moduladores de cck2 |
JP2008515956A (ja) * | 2004-10-12 | 2008-05-15 | ノボ ノルディスク アクティーゼルスカブ | 11β−ヒドロキシステロイドデヒドロゲナーゼ1型活性スピロ化合物 |
WO2007051811A2 (en) * | 2005-11-01 | 2007-05-10 | Transtech Pharma | Pharmaceutical use of substituted amides |
EP1948190A2 (en) * | 2005-11-01 | 2008-07-30 | Transtech Pharma | Pharmaceutical use of substituted amides |
JP2009530346A (ja) * | 2006-03-21 | 2009-08-27 | ハイ ポイント ファーマシューティカルズ,リミティド ライアビリティ カンパニー | メタボリックシンドロームの治療用のアダマンタン誘導体 |
WO2007115935A1 (en) | 2006-04-07 | 2007-10-18 | High Point Pharmaceuticals, Llc | 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS |
JP2009539937A (ja) * | 2006-06-16 | 2009-11-19 | ハイ ポイント ファーマシューティカルズ,リミティド ライアビリティ カンパニー | 置換型ピペリジンカルボキサミドの医薬的使用 |
US8048908B2 (en) * | 2006-07-13 | 2011-11-01 | High Point Pharmaceuticals, Llc | 11β-hydroxysteroid dehydrogenase type 1 active compounds |
EP1878721A1 (en) * | 2006-07-13 | 2008-01-16 | Novo Nordisk A/S | 4-Piperidylbenzamides as 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors |
WO2008101907A2 (en) * | 2007-02-23 | 2008-08-28 | High Point Pharmaceuticals, Llc | N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase |
JP2010519240A (ja) * | 2007-02-23 | 2010-06-03 | ハイ ポイント ファーマシューティカルズ,リミティド ライアビリティ カンパニー | 11−ベータ−ヒドロキシステロイドデヒドロゲナーゼの阻害剤としての、n−アダマンチルベンズアミド |
WO2008101914A2 (en) | 2007-02-23 | 2008-08-28 | High Point Pharmaceuticals, Llc | N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase |
JP2010519239A (ja) * | 2007-02-23 | 2010-06-03 | ハイ ポイント ファーマシューティカルズ,リミティド ライアビリティ カンパニー | 11−ベータ−ヒドロキシステロイドデヒドロゲナーゼの阻害因子としてのn−アドマンチルベンザミド |
AU2007349112A1 (en) * | 2007-03-09 | 2008-09-18 | High Point Pharmaceuticals, Llc | Indole- and benzimidazole amides as hydroxysteroid dehydrogenase inhibitors |
CN101679350B (zh) | 2007-03-22 | 2014-03-12 | 阿斯利康(瑞典)有限公司 | 用于治疗炎性疾病的喹啉衍生物 |
JP2010522766A (ja) * | 2007-03-28 | 2010-07-08 | ハイ ポイント ファーマシューティカルズ,リミティド ライアビリティ カンパニー | 11ベータ−hsd1活性化合物 |
EP2152081B1 (en) * | 2007-04-11 | 2012-10-24 | High Point Pharmaceuticals, LLC | Novel compounds |
EP2150109B1 (en) * | 2007-04-24 | 2012-09-19 | High Point Pharmaceuticals, LLC | Pharmaceutical use of substituted amides |
PE20091036A1 (es) | 2007-11-30 | 2009-08-15 | Astrazeneca Ab | Derivado de quinolina como antagonista del receptor p2x7 |
WO2010059618A1 (en) * | 2008-11-21 | 2010-05-27 | High Point Pharmaceuticals, Llc | Adamantyl benzamide compounds |
CN114369040B (zh) * | 2022-03-21 | 2022-07-05 | 广州同隽医药科技有限公司 | 2-(3-(对羟苯基)-丙酰胺基)-苯甲酸葡糖胺盐及其制备方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4343804A (en) * | 1979-03-26 | 1982-08-10 | A. H. Robins Company, Inc. | 4-Amino-3-quinolinecarboxylic acids and esters-antisecretory anti-ulcer compounds |
US4757151A (en) * | 1985-11-14 | 1988-07-12 | Warner-Lambert Company | 2-substituted-[2-substituted-amino]-N-arylalkyl-3-[indol-3-yl] |
US4814463A (en) * | 1985-12-31 | 1989-03-21 | Biomeasure, Inc. | CCK antagonists |
CA1326108C (en) * | 1988-04-12 | 1994-01-11 | Sun Hyuk Kim | Cck antagonists |
JPH04211661A (ja) * | 1990-03-28 | 1992-08-03 | Otsuka Pharmaceut Co Ltd | キノリン誘導体及び該誘導体を含有する抗潰瘍剤 |
US5217957A (en) * | 1991-08-20 | 1993-06-08 | Warner-Lambert Company | Cholecystokinin antagonists useful for treating depression |
GB9206757D0 (en) * | 1992-03-27 | 1992-05-13 | Ferring Bv | Novel peptide receptor ligands |
US5795907A (en) * | 1994-05-27 | 1998-08-18 | James Black Foundation Limited | Gastin and CCK receptor ligands |
-
1994
- 1994-08-09 ES ES94922318T patent/ES2152989T3/es not_active Expired - Lifetime
- 1994-08-09 SG SG1996000865A patent/SG52229A1/en unknown
- 1994-08-09 AT AT94922318T patent/ATE197146T1/de not_active IP Right Cessation
- 1994-08-09 WO PCT/GB1994/001741 patent/WO1995004720A2/en active IP Right Grant
- 1994-08-09 AU AU73478/94A patent/AU682051B2/en not_active Ceased
- 1994-08-09 CA CA002167154A patent/CA2167154A1/en not_active Abandoned
- 1994-08-09 JP JP50630695A patent/JP3980052B2/ja not_active Expired - Lifetime
- 1994-08-09 EP EP94922318A patent/EP0720601B1/en not_active Expired - Lifetime
- 1994-08-09 PL PL94312960A patent/PL181782B1/pl not_active IP Right Cessation
- 1994-08-09 DK DK94922318T patent/DK0720601T3/da active
- 1994-08-09 HU HU9600070A patent/HU222178B1/hu active IP Right Grant
- 1994-08-09 NZ NZ269827A patent/NZ269827A/en not_active IP Right Cessation
- 1994-08-09 DE DE69426205T patent/DE69426205T2/de not_active Expired - Fee Related
- 1994-08-09 PT PT94922318T patent/PT720601E/pt unknown
-
1996
- 1996-02-06 NO NO960488A patent/NO306945B1/no unknown
- 1996-02-07 FI FI960572A patent/FI115050B/fi active IP Right Grant
-
1998
- 1998-04-23 US US09/064,849 patent/US5919829A/en not_active Expired - Fee Related
-
2000
- 2000-12-18 GR GR20000402788T patent/GR3035100T3/el not_active IP Right Cessation
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006501194A (ja) * | 2002-07-03 | 2006-01-12 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Cck−1受容体モジュレーター |
WO2006095922A1 (ja) * | 2005-03-10 | 2006-09-14 | Kyoto Pharmaceutical Industries, Ltd. | テトラヒドロイソキノリン化合物およびその医薬用途 |
Also Published As
Publication number | Publication date |
---|---|
SG52229A1 (en) | 1998-09-28 |
DE69426205D1 (de) | 2000-11-30 |
AU682051B2 (en) | 1997-09-18 |
NZ269827A (en) | 1996-10-28 |
WO1995004720A2 (en) | 1995-02-16 |
NO960488L (no) | 1996-03-15 |
ES2152989T3 (es) | 2001-02-16 |
WO1995004720A3 (en) | 1995-08-03 |
EP0720601B1 (en) | 2000-10-25 |
PL312960A1 (en) | 1996-05-27 |
EP0720601A1 (en) | 1996-07-10 |
FI960572A (fi) | 1996-02-07 |
ATE197146T1 (de) | 2000-11-15 |
FI115050B (fi) | 2005-02-28 |
FI960572A0 (fi) | 1996-02-07 |
DK0720601T3 (da) | 2000-11-20 |
US5919829A (en) | 1999-07-06 |
HU9600070D0 (en) | 1996-03-28 |
CA2167154A1 (en) | 1995-02-16 |
HUT75301A (en) | 1997-05-28 |
NO960488D0 (no) | 1996-02-06 |
PL181782B1 (pl) | 2001-09-28 |
HU222178B1 (hu) | 2003-04-28 |
PT720601E (pt) | 2001-02-28 |
JP3980052B2 (ja) | 2007-09-19 |
AU7347894A (en) | 1995-02-28 |
NO306945B1 (no) | 2000-01-17 |
DE69426205T2 (de) | 2001-03-08 |
GR3035100T3 (en) | 2001-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH09502430A (ja) | ガストリンとcckレセプタリガンド | |
US5795907A (en) | Gastin and CCK receptor ligands | |
US5939437A (en) | CCK and gastrin receptor ligands | |
TWI283670B (en) | 5-sulphanyl-4h-1,2,4-triazole derivatives and their use as a medicament | |
EP0950047B1 (fr) | Derives d'indolin-2-one, procede pour leur preparation et compositions pharmaceutiques les contenant | |
RU2130923C1 (ru) | Производные глицинамида, способ их получения, промежуточные продукты и фармацевтическая композиция | |
WO2007012661A1 (fr) | Composes derives d'hydantoïne et leur utilisation en tant qu'antagonistes de mchr-1 | |
CZ283602B6 (cs) | Pyrrolidinové deriváty, způsob jejich přípravy a léčiva tyto deriváty obsahující | |
JPH10504525A (ja) | ガストリンとcck拮抗薬 | |
JP2002529455A (ja) | ガストリンおよびコレシストキニン受容体リガンド類 | |
WO1995018105A1 (fr) | Derives de 1,3-dihydroindol-2-one substitues en 3 par un groupe azote comme agonistes et/ou antagonistes de la vasopressine et/ou de l'ocytocine | |
AU1069800A (en) | 3-azabicyclo(3.1.0.) hexane derivatives as opiate receptors ligands | |
JPH03279374A (ja) | 異項環置換アシルアミノチアゾール | |
LV11028B (en) | Novel benzimidazole and azabenzimidazole derivatives | |
IE914293A1 (en) | N-substituted lactams useful as cholecystokinin antagonists | |
US5674905A (en) | Bicyclooctane and bicycloheptane derivatives | |
WO1993016982A1 (en) | Bicyclo[2.2.2.]octane derivatives as cholestocystokinin inhibitors | |
Boyle et al. | 7-Aroyl-2, 3-dihydrobenzo [b] furan-3-carboxylic acids and 7-benzoyl-2, 3-dihydrobenzo [b] thiophene-3-carboxylic acids as analgesic agents | |
US5514683A (en) | Bicyclo 2,2,2!octane derivatives | |
US5591866A (en) | (1H-indol-1-yl)-2-(amino)acetamide derivatives and preparation thereof | |
KR20060130123A (ko) | 프로스타글란딘 e2 작용제 또는 길항제로서의 오르니틴유도체 | |
WO1998046569A1 (fr) | Derives de benzene | |
KR100299419B1 (ko) | 가스트린및cck수용체리간드 | |
GB2268739A (en) | Bicyclo [2.2.2.] octene derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060131 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20060428 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20060619 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060731 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20061003 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20061228 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070219 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070330 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20070529 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20070627 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100706 Year of fee payment: 3 |